Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P190002/S039

CAP24 Paddle Lead, Passing Elevator, Evoke CLS (REF 3042), Clarity Programming Application (CPA), and RECAP Viewer

Saluda Medical Pty, Ltd. · Decision date Jun 29, 2026

FDA DECISIONP190002/S039

What did the FDA approve?

FDA records P190002/S039 as a supplement to PMA P190002, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jun 29, 2026.

FDA approval order statement

Approval for the CAP24 Paddle Lead and Passing Elevator components, software updates to the Clarity Clinical Programming Application (CPA) and RECAP Viewer (CDV) to support the CAP24 Paddle Lead and include minor bug fixes and improvements, and labeling updates to support these changes. Software changes required for use of the paddle lead with the Evoke Spinal Cord Stimulation (SCS) System were also approved in P190002/S038.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Neurology
Decision date
Jun 29, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P190002/S039
Regulatory pathway
PMA supplement
Product code
LGW
Decision code
APPR
Decision date
Jun 29, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.

Product code
LGW
FDA device class
3

For the original device and its historical approval scope, see PMA P190002. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P190002 · Original PMA

    Saluda Medical Evoke SCS System

  2. P190002/S039 received

    Application receipt date recorded by FDA.

  3. P190002/S041 · Related supplement

    Saluda Medical Evoke SCS System

  4. P190002/S045 · Related supplement

    Saluda Medical Evoke SCS System

  5. P190002/S036 · Related supplement

    Saluda Medical Evoke SCS System

  6. P190002/S049 · Related supplement

    Saluda Medical Evoke SCS System

  7. P190002/S038 · Related supplement

    Saluda Medical Evoke SCS System; Closed Loop Stimulator (CLS) (REF: 3042)

  8. P190002/S039 · FDA decision

    Normal 180 Day Track

  9. P190002/S051 · Related supplement

    Saluda Medical Evoke SCS System

  10. P190002/S052 · Related supplement

    Saluda Medical Evoke SCS System

Timeline entries are records held by MedtechLedger for P190002. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190002

Product / regulatory recordCompanyPathwayDecision dateSource
Saluda Medical Pty, Ltd.PMA approvalFeb 28, 2022FDA
Saluda Medical Pty, Ltd.PMA supplementAug 21, 2025FDA
Saluda Medical Pty, Ltd.PMA supplementNov 8, 2025FDA
Saluda Medical Pty, Ltd.PMA supplementJan 6, 2026FDA
Evoke SCS SystemP190002/S048
Saluda Medical Pty, Ltd.PMA supplementJun 12, 2026FDA
Saluda Medical Pty, Ltd.PMA supplementJun 12, 2026FDA
Saluda Medical Pty, Ltd.PMA supplementJun 29, 2026FDA
Saluda Medical Pty, Ltd.PMA supplementOct 15, 2026FDA
Saluda Medical Pty, Ltd.PMA supplementOct 16, 2026FDA

Explore the linked device profile

Other records with product code LGW

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Saluda Medical Pty, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Level 1, 407 Pacific Hwy., Atarmon, NSW 2064

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records